OMB No. 3117-0016/USITC No. 05-2-2274; Expiration Date: 6/30/05
(No response is required if currently valid OMB control number is not displayed)

IMPORTERS' QUESTIONNAIRE

POLYCHLOROPRENE RUBBER FROM JAPAN

Return completed questionnaire to:

UNITED STATES INTERNATIONAL TRADE COMMISSION
Office of Investigations, Room 615
500 E Street, SW, Washington, DC 20436

So as to be received by the Commission by no later than March 3, 2005

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping review investigation concerning polychloroprene rubber (PCR) from Japan (inv. No. AA1921-129 (Second Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your possession (19 U.S.C. § 1333(a)).

Name of firm _____

Address _____

City _____ **State** _____ **Zip code** _____

World Wide Web address _____

Has your firm imported PCR (as defined in the instruction booklet) from any country at any time since January 1, 1999?

☐ **NO** (Sign the certification below and promptly return only this page of the questionnaire to the Commission)

☐ **YES** (Read the instruction booklet carefully, complete all parts of the questionnaire, sign the certification, and return the entire questionnaire to the Commission)

CERTIFICATION

I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge and belief and understand that the information submitted is subject to audit and verification by the Commission.

By signing this certification I also grant consent for the Commission, and its employees and contract personnel, to use the information provided in this questionnaire and throughout this review in any other import-injury investigations or reviews conducted by the Commission on the same or similar merchandise. (If you do not consent to such use, please note the certification accordingly.)

I acknowledge that information submitted in this questionnaire response and throughout this review may be used by the Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or maintaining the records of this review or related proceedings for which this information is submitted, or in internal audits and investigations relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all contract personnel will sign non-disclosure agreements.

_____ _____
Name and Title of Authorized Official ***Date***

_____ ***(___)*** _____ ***(___)*** _____
Signature of Authorized Official ***Phone*** ***Fax***

PART I.--GENERAL QUESTIONS

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 20 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

I-1a. Please report below the actual number of hours required and the cost to your firm of preparing the reply to this questionnaire and completing the form.

_____ hours _____ dollars

I-1b. We are interested in any comments you may have for improving this questionnaire in general or the clarity of specific questions. Please attach such comments to your response or send them to the above address.

I-2. Provide the name and address of establishment(s) covered by this questionnaire (see pages 3-4 of the instruction booklet for reporting guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol.

_____

_____

_____

I-3. Is your firm owned, in whole or in part, by any other firm?

☐ No ☐ Yes--List the following information.

Firm name	Address	Extent of ownership

I-4. Does your firm have any related firms, either domestic or foreign, which are engaged in importing PCR from Japan into the United States or which are engaged in exporting PCR from Japan to the United States?

☐ No ☐ Yes--List the following information.

Firm name	Address	Affiliation

PART I.--GENERAL QUESTIONS--*Continued*

I-5. Does your firm have any related firms, either domestic or foreign, which are engaged in importing PCR from countries other than Japan into the United States or which are engaged in exporting PCR from countries other than Japan to the United States?

☐ No ☐ Yes--List the following information.

Country/firm name	Address	Affiliation

I-6. Does your firm have any related firms, either domestic or foreign, which are engaged in the production of PCR?

☐ No ☐ Yes--List the following information.

Firm name	Address	Affiliation

I-7. Please indicate the nature of your firm's importing operations on PCR. More than one answer may be applicable.

☐ Importer of record ☐ Takes title to the imported product(s)

☐ Consignee of the imported product(s) ☐ Customs broker or freight forwarder

I-8. If your firm is an importer of record of PCR but is **not** the consignee, please list the consignees below (company name, address, telephone, and individual to contact).

I-9. Please indicate whether your firm enters PCR into, or withdraws such merchandise from, foreign trade zones or bonded warehouses.

Foreign trade zones ☐ No ☐ Yes--list location(s):

Bonded warehouses ☐ No ☐ Yes–list location(s):

PART I.--GENERAL QUESTIONS--*Continued*

I-10. Please indicate whether your firm imports PCR under the TIB (temporary importation under bond) program.

☐ No ☐ Yes

I-11. In Parts II and III of this questionnaire we request a copy of your company's most recent business plans. Does your company or any related firm have a business plan or any internal documents that describe, discuss, or analyze expected future market conditions for PCR?

☐ No ☐ Yes--Please provide the requested documents. If you are not providing the requested documents, please explain why not.

_____

_____

I-12. To your knowledge, have the products subject to this review been the subject of any other import relief investigations in the United States or in any other countries?

☐ No ☐ Yes--Please specify.

_____

_____

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from John Kitzmiller (202-205-3387). **Supply all data requested on a calendar-year basis.**

II-1. Who should be contacted regarding the requested trade and related information?

Company contact: _____
Name and title

_____ _____
Phone No. E-mail address

II-2. Has your firm experienced any plant openings, relocations, expansions, acquisitions, consolidations, closures, or prolonged shutdowns because of strikes or equipment failure, or any other change in the character of your operations or organization relating to the importation of PCR since December 6, 1973 (the date on which the antidumping finding under review became effective)?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes.

_____

_____

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-3. Does your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the importation of PCR in the future?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

II-4. Would your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the importation of PCR in the future if the antidumping finding on PCR from Japan were to be revoked?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

II-5. Has your firm imported or arranged for the importation of PCR from Japan for delivery after December 31, 2004?

☐ No ☐ Yes--Indicate when such orders are to be delivered and the quantities involved.

II-6. If your firm also produces PCR in the United States, please indicate your reasons for importing this product. If your reasons differ by source, please elaborate.

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-7. **IMPORTS BY SOURCE**.--Report your firm's imports and your firm's shipments and inventories of PCR imported by your firm during **1999-2004**. (See definitions in the instruction booklet.) **Report separately for Japan and for all other sources combined. Photocopy as many pages as you need and identify the source for which you are reporting in the space provided.**

☐ Japan (from Denki Kagaku Kogyo KK) ☐ Japan (other than from Denki Kagaku Kogyo KK)
☐ All other sources combined[1]

(*Quantity* in 1,000 pounds, *value* in $1,000)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
BEGINNING-OF-PERIOD INVENTORIES (*quantity*)						
IMPORTS:[2]						
Quantity of imports						
Value of imports						
U.S. SHIPMENTS:						
Commercial shipments:						
Quantity of commercial shipments						
Value of commercial shipments						
Internal consumption/company transfers:						
Quantity of internal consumption/transfers						
Value[3] of internal consumption/transfers						
EXPORT SHIPMENTS:[4]						
Quantity of export shipments						
Value of export shipments						
END-OF-PERIOD INVENTORIES[5] (*quantity*)						
U.S. SHIPMENTS TO DISTRIBUTORS (*quantity*)						
U.S. SHIPMENTS TO END USERS (*quantity*)						

[1] Please identify these sources: _____

_____

[2] Please identify the foreign producers, if known: _____

_____

[3] Sales to related firms (including internal consumption) must be valued at fair market value. In the event that you use a different basis for valuing these sales within your company, please specify that basis (e.g., cost, cost plus, etc.) and provide value data using that basis for 1999-2004 below:

_____

_____

[4] Identify your principal export markets: _____

_____

[5] Reconciliation of data.--Please note that the **quantities** reported above should reconcile as follows: beginning-of-period inventories, plus imports, less total shipments, equals end-of-period inventories. Do the data reported reconcile?

☐ Yes ☐ No--Please explain: _____

_____

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-8. Report your firm's total U.S. shipments of PCR for the specified end uses. Totals should conform to the sum of U.S. commercial shipments and U.S. internal consumption reported in response to question II-7.

(*Quantity* in 1,000 pounds)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
Adhesives and sealants						
Belts and hoses						
Latex and dipped goods						
Wire and cable						
Other						
Unknown						
Total						

II-9. Describe the significance of the existing antidumping finding covering imports of PCR from Japan in terms of its effect on your firm's imports, U.S. shipments of imports, and inventories. You may wish to compare your firm's operations before and after the finding.

II-10. Would your firm anticipate any changes in its imports, U.S. shipments of imports, or inventories of PCR in the future if the antidumping finding on PCR from Japan were to be revoked?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, for any trends or projections you may provide.

PART III.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Robert Hughes (202-205-3300).

III-1. Who should be contacted regarding the requested pricing and related information?

Company contact: _____
Name and title

_____ _____
Phone No. E-mail address

Section III-A.--PRICING DATA

This section requests pricing information for the following products:

***Product 1*.–PCR for industrial goods; a sulfur-modified type with Mooney viscosity 36 to 55, equivalent to DuPont Dow type GRT or Denka type PS40, in solid "chips."**

***Product 2*.--PCR for industrial goods, with low temperature resistance, high crystallization resistance, Mooney viscosity 43 to 53, equivalent to DuPont Dow type WRT or Denka type S-40V, in solid "chips."**

***Product 3*.--PCR for general purpose solvent-based adhesives, equivalent to DuPont Dow type AD or Denka type A.**

***Product 4*.--PCR equivalent to DuPont Dow type SND35 or Denka type DCR35, in solid "chips."**

☐ Check here if your firm imports PCR from Japan and sells these products to unrelated U.S. companies. Report the selling price data requested in section III-A.1.

☐ Check here if your firm imports PCR from Japan for your own use. Report the purchase price data requested in section III-A.2.

COPY THE FOLLOWING PAGES AS NECESSARY. Complete a separate page for each of the specified products imported by your firm. Indicate in the space provided the product for which pricing is reported.

Note: If your firm imported PCR from Denki Kagaku Kogyo KK, please do not include the quantities and values of these data in your firm's sales of Japanese PCR that are reported below.

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-A.1.–**SELLING PRICE DATA**-- This section requests quarterly quantity and value data on your firm's U.S. shipments during 1999-2004 that you imported from Japan (other than from Denki Kagaku Kogyo KK).

☐ **Product 1** ☐ **Product 2** ☐ **Product 3** ☐ **Product 4**

(*Quantity* in pounds, *value* in dollars)		
Period of shipment	**Quantity**	**Value[1]**
1999:		
January-March		
April-June		
July-September		
October-December		
2000:		
January-March		
April-June		
July-September		
October-December		
2001:		
January-March		
April-June		
July-September		
October-December		
2002:		
January-March		
April-June		
July-September		
October-December		
2003:		
January-March		
April-June		
July-September		
October-December		
2004:		
January-March		
April-June		
July-September		
October-December		

[1] Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your U.S. point of shipment.

Note.--If your product does not exactly meet the product specifications but is competitive with the specified product, provide a description of your product:

_____

PART III.–PRICING AND RELATED INFORMATION–*Continued*

Section III-A.2.–PURCHASE PRICE DATA-- This section requests quarterly quantity and delivered value data for your firm's direct import purchases for your own use during 1999-2004 from Japan (other than from Denki Kagaku Kogyo KK).

☐ **Product 1** ☐ **Product 2** ☐ **Product 3** ☐ **Product 4**

(*Quantity* in pounds, *value* in dollars)		
Period of shipment	**Quantity**	**Delivered Value[1]**
1999:		
January-March		
April-June		
July-September		
October-December		
2000:		
January-March		
April-June		
July-September		
October-December		
2001:		
January-March		
April-June		
July-September		
October-December		
2002:		
January-March		
April-June		
July-September		
October-December		
2003:		
January-March		
April-June		
July-September		
October-December		
2004:		
January-March		
April-June		
July-September		
October-December		

[1] Delivered value should be net of returns, discounts, allowances, and rebates, but should include all ocean freight costs and U.S.-inland freight costs for delivery to your facility.

Note.--If your product does not exactly meet the product specifications but is competitive with the specified product, provide a description of your product:

_____

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--PRICE-RELATED QUESTIONS

Please note that the questions in this section refer to the entire period since 1973, unless otherwise specified. If your response to any question differs for different time periods since 1973, please note this in your response (identifying the month/year to which you are referring).

III-B-1. Please describe how your firm determines the prices that it charges for sales of PCR (transaction by transaction negotiation, contracts for multiple shipments, set price lists, etc.). If your firm issues price lists, please include a copy of a recent price list with your submission. If your price list is large, please submit sample pages.

III-B-2. Please describe your firm's discount policy (quantity discounts, annual total volume discounts, etc.).

III-B-3. What are your firm's typical sales terms for PCR imported from Japan (e.g., 2/10 net 30 days)? _____ On what basis are your prices of such product usually quoted (e.g., f.o.b. port of entry, or delivered)? _____

III-B-4. Approximately what share of your firm's sales of its PCR imported from Japan in 2004 were on a (1) long-term contract basis (multiple deliveries for more than 12 months), (2) short-term contract basis (multiple deliveries up to 12 months), and (3) spot sales basis (for a single delivery)?

Type of sale	Share of sales (percent)
Long-term contracts	
Short-term contracts	
Spot sales	

III-B-5. If you sell on a long-term contract basis, please answer the following questions with respect to provisions of a typical long-term contract.

(a) What is the average duration of a contract? _____

(b) Can prices be renegotiated during the contract period? _____

(c) Does the contract fix quantity, price, or both? _____

(d) Does the contract have a meet or release provision? _____

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--PRICE-RELATED QUESTIONS

III-B-6. If you sell on a short-term contract basis, please answer the following questions with respect to provisions of a typical short-term contract.

(a) What is the average duration of a contract? _____

(b) Can prices be renegotiated during the contract period? _____

(c) Does the contract fix quantity, price, or both? _____

(d) Does the contract have a meet or release provision? _____

III-B-7. What is the average lead time between a customer's order and the date of delivery for your firm's sales of PCR?

Source	Share of 2004 sales	Lead time
From inventory		
Produced to order		
Total	**100%**	

III-B-8. (a) What is the approximate percentage of the total delivered cost of PCR that is accounted for by U.S. inland transportation costs? _____ percent.

(b) Who generally arranges the transportation to your customers' locations? Your firm _____ or purchaser _____ (check one).

(c) Approximately what proportion of your sales occur within 100 miles of your storage or production facility? _____ percent. 101 to 1,000 miles? _____ percent. Over 1,000 miles? _____ percent.

III-B-9. What is the geographic market area in the United States served by your firm's PCR?

☐ Northeast ☐ Mid-Atlantic ☐ Midwest ☐ Southeast

☐ Southwest ☐ Rocky Mountains ☐ West Coast ☐ Northwest

☐ National ☐ Other (describe) _____

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--PRICE-RELATED QUESTIONS--*Continued*

III-B-10. Describe the end uses of the PCR that you import from Japan. For each end-use product, what percentage of the total cost is accounted for by PCR?

End use	Share of total cost accounted for by PCR (percent)

III-B-11. Have there been any changes in the end uses of PCR since 1973?

☐ No ☐ Yes--Please describe.

III-B-12. Do you anticipate any changes in terms of the end uses of PCR in the future?

☐ No ☐ Yes--Please describe and identify the time period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

III-B-13. (a) Please list in order of importance any products that may be substituted for PCR.

(1) _____ (2) _____ (3) _____

(b) For each possible substitute product, please give examples of applications and end uses for which they are substitutes.

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--PRICE-RELATED QUESTIONS--*Continued*

III-B-14. (c) Have changes in the prices of these products affected the price for PCR?

☐ No ☐ Yes–To what degree do changes in their prices affect the price for PCR? Does this effect have a time lag? If so, how long is the time lag for each substitute product? Does this vary by type of PCR or final end use?

III-B-15. Have there been any changes in the number or types of products that can be substituted for PCR since 1973?

☐ No ☐ Yes--Please explain.

III-B-16. Do you anticipate any changes in terms of the substitutability of other products for PCR in the future?

☐ No ☐ Yes--Please describe. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

III-B-17. To what extent have changes in the prices of raw materials affected your firm's selling prices for PCR during 1999-2004? Also discuss any anticipated changes in your raw material costs in the future, identifying the time period(s) involved and the factor(s) that you believe would be responsible for such changes. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--PRICE-RELATED QUESTIONS--*Continued*

III-B-18. Have any changes occurred in any other factors affecting supply (e.g., changes in availability or prices of energy or labor; transportation conditions; production capacity and/or methods of production; technology; export markets; or alternative production opportunities) that affected the availability of U.S.-produced PCR in the U.S. market since 1973?

☐ No ☐ Yes--Please note the time period(s) of any such changes, the factors(s) involved, and the impact such changes had on your shipment volumes and prices.

III-B-19. (a) Do you anticipate any changes in terms of the availability of PCR imported from Japan in the U.S. market in the future?

☐ Increase ☐ No Change ☐ Decrease

(b) If you anticipate changes in supply, please identify the changes including the time period and the impact of such changes on shipment volumes and prices. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

III-B-20. Has the availability of NONSUBJECT imported PCR changed since 1973?

☐ No ☐ Yes--Please explain.

III-B-21. Describe how easily your firm can shift its sales of PCR between the U.S. market and alternative country markets. In your discussion, please describe any contracts, other sales arrangements, or other constraints that would prevent or retard your firm from shifting PCR between the U.S. and alternative country markets within a 12-month period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--PRICE-RELATED QUESTIONS--*Continued*

III-B-22. Have there been any significant changes in the product range, product mix, or marketing (including sales over the internet) of PCR since 1973?

☐ No ☐ Yes--Please describe and quantify if possible.

_____

_____

III-B-23. Do you anticipate any changes in terms of the product range, product mix, or marketing (including sales over the internet) of PCR in the future? Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

☐ No ☐ Yes--Please identify, including the time period.

_____

_____

III-B-24. How has demand within the United States (and outside the United States, if known) for PCR changed since 1973?

☐ Increased ☐ Unchanged ☐ Decreased

☐ Other (describe) _____

What were the principal factors affecting changes in demand?

_____

_____

III-B-25. Do you anticipate any future changes in PCR demand in the United States and, if known, the rest of the world?

☐ No ☐ Yes--Please describe and identify the time period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

_____

_____

_____

_____

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--MARKET FACTORS--*Continued*

III-B-26. Please compare market prices of PCR in U.S. and non-U.S. markets, if known. Provide specific information as to time periods and regions for any price comparisons.

III-B-27. Please provide as a separate attachment to this request any studies, surveys, etc. that you are aware of that quantify and/or otherwise discuss PCR supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major producing/consuming countries, including Japan, and (3) the world as a whole. Of particular interest is such data from 1973 to the present and forecasts for the future.

III-B-28. Are your exports of PCR subject to any tariff or non-tariff barriers to trade in other countries?

☐ No ☐ Yes--Please list the countries and describe any such barriers and any significant changes in such barriers that have occurred since 1973, or that are expected to occur in the future.

III-B-29. Does your firm sell PCR over the internet?

☐ No ☐ Yes--Please describe, noting the estimated percentage of your firm's total sales of PCR in 2004 accounted for by internet sales.

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--PRICE-RELATED QUESTIONS--*Continued*

III-B-30. Is PCR produced in the United States and in other countries interchangeable (i.e., can they physically be used in the same applications)? Please indicate below, using "A" to indicate that the products from a specified country-pair are *always* interchangeable, "F" to indicate that the products are *frequently* interchangeable,"S" to indicate that the products are *sometimes* interchangeable,"N" to indicate that the products are *never* interchangeable, and "0" to indicate *no familiarity* with products from a specified country-pair.[1]

Country-pair	United States	Japan	Other countries
United States			
Japan			

[1] For any country-pair producing PCR which is *sometimes or never* interchangeable, please explain the factors that limit or preclude interchangeable use:

PART III.--PRICING AND MARKET FACTORS--*Continued*

Section III-B.--PRICE-RELATED QUESTIONS--*Continued*

III-B-31. Are differences other than price (i.e., quality, availability, transportation network, product range, technical support, etc.) between PCR produced in the United States and in other countries a significant factor in your firm's sales of the products? Please indicate below, using "A" to indicate that such differences are *always* significant, "F" to indicate that such differences are *frequently* significant,"S" to indicate that such differences are *sometimes* significant,"N" to indicate that such differences are *never* significant, and "0" to indicate *no familiarity* with products from a specified country-pair.[1]

Country-pair	United States	Japan	Other countries
United States			
Japan			

[1] For any country-pair for which factors other than price *always or frequently* are a significant factor in your firm's sales of PCR, identify the country-pair and report the advantages or disadvantages imparted by such factors: